Hara et al. [73] found that DLX4 promoted ovarian tumor through its control of a proangiogenic molecular program involving fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF). Here, FGF2 is linked to ovarian neoplasm.